北京航天长峰股份有限公司 因此不存在影响独立性的情况。 二、年度履职情况 （一）参加董事会、股东大会会议情况。 2024 年度独立董事述职报告 作为北京航天长峰股份有限公司（以下简称"公司"或"航天长 峰"）的独立董事，我严格按照《中华人民共和国公司法》《上市公 司治理规则》《上市公司独立董事管理办法》《上海证券交易所股票 上市规则》等法律法规及《公司章程》《公司独立董事管理办法》等 相关规定和要求，恪尽职守，勤勉尽责，及时了解公司的业务发展状 况、财务运作状况，全面关注公司的成长，积极出席相关会议，认真 审议董事会各项议案，认真履行了独立董事的职责，有效保证了董事 会决策的科学性和公司运作的规范性，切实维护了全体股东尤其是中 小股东的合法权益。现将本人2024年度履行职责情况报告如下： 一、独立董事的基本情况 惠汝太，1951年生，1975年毕业于山东医学院医疗系，1977年— 1978年在北京大学人民医院内科进修，1979年—1982年考入中国协和 医科大学高血压专业攻读硕士学位，毕业留院担任心内科主治医师， 1987年—1992年在加拿大蒙特利尔临床医学研究所攻读临床科学博 士学位，1993年—1996 ...

Financial Performance - The company's net profit attributable to shareholders for 2024 was -245.94 million RMB, a decline from -235.21 million RMB in 2023[5]. - Total operating revenue for 2024 was 1.16 billion RMB, representing a decrease of 16.09% compared to 1.38 billion RMB in 2023[22]. - The net cash flow from operating activities was -12.23 million RMB, worsening from -3.47 million RMB in the previous year[22]. - The total assets at the end of 2024 were 3.72 billion RMB, down 6.56% from 3.98 billion RMB at the end of 2023[23]. - The net assets attributable to shareholders decreased by 13.23% to 1.61 billion RMB from 1.85 billion RMB in 2023[23]. - The company reported a revenue of 1.16 billion RMB in 2024, with a net profit attributable to shareholders of -246 million RMB, indicating a significant decline in performance compared to previous years[24]. - The company recorded a basic earnings per share of -0.5259 RMB in 2024, compared to -0.5030 RMB in 2023[24]. - The weighted average return on equity improved slightly to -14.20% in 2024 from -14.33% in 2023[24]. - Net profit for the period was -265 million RMB, with a net profit attributable to shareholders of -246 million RMB[47]. Revenue Breakdown - Revenue from the high-end medical equipment sector decreased by 79.99% year-on-year, while net profit fell by 65.5 million RMB[25]. - The military electronics sector experienced an 11.43% decline in revenue year-on-year, with net profit improving by 33.86 million RMB, primarily due to a 30.27% drop in infrared optoelectronic business revenue[25]. - The public safety sector's revenue decreased by 7.53% year-on-year, with net profit declining by 37.63 million RMB, attributed to insufficient market demand and increased impairment provisions[25]. - The company achieved operating revenue of 1.16 billion RMB, a year-on-year decrease of 16.09% due to reduced income from public safety and military electronic infrared optical businesses[47]. Strategic Initiatives - The company plans not to distribute profits or increase capital reserves for 2024 due to overall performance losses[5]. - The company plans to address the decline in high-end medical equipment sales through market expansion strategies[25]. - The company is focusing on core development strategies and has completed mid-term evaluations and adjustments of the "14th Five-Year Plan"[37]. - The company is actively promoting new products and technologies, including the NO inhalation therapy device, and has published two provincial standards[44]. - The company is committed to the development of high-end medical equipment, focusing on domestic production and innovation[41]. - The company is enhancing its market position and influence in the aerospace defense industry through strategic resource allocation[37]. - The company is focusing on optimizing traditional power products and developing overall solutions for different application scenarios in the power sector[86]. Research and Development - The company’s total R&D investment amounted to 9,204.70 million RMB, representing 7.94% of total operating revenue[62]. - The company has 245 R&D personnel, making up 17.66% of the total workforce[63]. - The company launched 79 self-funded R&D projects, with 38 new projects initiated during the year[64]. - The company is focusing on high-tech, high-value-added product development, including advanced medical equipment and military electronics[65]. - The company is investing in R&D to address technological innovation risks, focusing on key core technologies and establishing partnerships with research institutions[96]. Governance and Compliance - The company has established a governance mechanism that enhances decision-making efficiency and reduces risks through clear authority and responsibility[100]. - The company emphasizes transparency and timely information disclosure to manage investor relations effectively[100]. - The company has implemented measures to ensure the independence of its operations and governance structure, complying with relevant laws and regulations[101]. - The company’s board of directors and supervisory board are functioning effectively, ensuring compliance with governance rules[102]. - The company has a clear plan for future governance improvements, focusing on risk management and operational efficiency[100]. Environmental and Social Responsibility - The company invested 5.136 million yuan in environmental protection during the reporting period[137]. - The company has identified 21 pollution discharge points and implemented management measures to enhance responsibility[139]. - All units have passed ISO 14001:2015 environmental management system certification in 2024[144]. - The company has organized training for over 200 employees on energy conservation and environmental protection laws and regulations[145]. - The company engaged in consumption assistance, purchasing local specialty foods worth 244,900 yuan to support targeted poverty alleviation[148]. Shareholder and Market Activities - The company repurchased and canceled a total of 72,150 shares, with an average price of 51.21[104]. - The total number of shares repurchased and canceled amounts to 69,1020, with a total value of 444.16 million[104]. - The company reported a total revenue of 51,444.36 million yuan and a net loss of 8,538.35 million yuan for the period[81]. - The company aims to achieve a revenue growth target of 15% year-over-year in the next fiscal year[105]. - The largest shareholder, China Aerospace Science and Industry Corporation, holds 141,150,722 shares, representing 30.13% of total shares[197].

Financial Performance - The company reported a revenue of CNY 99,810,834.68 for Q1 2025, a decrease of 33.89% compared to CNY 150,972,476.99 in the same period last year[4] - Total operating revenue for Q1 2025 was RMB 99,810,834.68, a decrease of 34% compared to RMB 150,972,476.99 in Q1 2024[19] - The net profit for Q1 2025 was a loss of CNY 48,213,192.40, compared to a loss of CNY 47,430,829.62 in Q1 2024, indicating a slight increase in losses of about 1.64%[21] - The total comprehensive income for Q1 2025 was a loss of CNY 48,213,192.40, compared to a loss of CNY 47,430,829.62 in Q1 2024, showing a slight increase in losses of about 1.64%[21] - The company's revenue for Q1 2025 was CNY 3,837,207.44, a decrease of 60.7% compared to CNY 9,751,509.56 in Q1 2024[30] - Operating profit for Q1 2025 was CNY -17,142,835.92, an improvement from CNY -26,261,635.18 in Q1 2024[30] - Net profit for Q1 2025 was CNY -17,139,835.82, compared to CNY -26,262,180.56 in Q1 2024, indicating a reduced loss[30] Cash Flow and Liquidity - The net cash flow from operating activities was CNY -130,862,574.77, worsening from CNY -72,483,482.20 in the previous year[5] - The cash flow from operating activities for Q1 2025 was a net outflow of CNY 130,862,574.77, worsening from a net outflow of CNY 72,483,482.20 in Q1 2024[23] - The total cash and cash equivalents at the end of Q1 2025 were CNY 653,264,910.70, down from CNY 848,867,259.38 at the end of Q1 2024, reflecting a decrease of approximately 23%[24] - The cash flow statement indicates a challenging liquidity position with a significant decrease in cash reserves compared to the previous period[34] - The company's cash flow from operating activities showed a significant decrease in cash outflows, with total cash outflows of CNY 20,942,844.61 in Q1 2025 compared to CNY 40,434,963.40 in Q1 2024[33] Assets and Liabilities - The total assets at the end of the reporting period were CNY 3,593,449,934.15, a decrease of 3.45% from CNY 3,721,891,711.89 at the end of the previous year[5] - Current assets totaled RMB 2,765,821,438.32 as of March 31, 2025, down from RMB 2,898,540,043.57 as of December 31, 2024, reflecting a decrease of approximately 4.6%[15] - Total liabilities amounted to RMB 1,906,121,151.47 as of March 31, 2025, compared to RMB 1,986,651,956.59 at the end of 2024, indicating a reduction of about 4%[17] - The company's total equity decreased to CNY 2,067,892,203.01 from CNY 2,085,032,038.83, a decline of 0.8%[28] - The total equity attributable to shareholders decreased to RMB 1,566,833,162.20 from RMB 1,609,351,070.15, reflecting a decline of approximately 2.6%[17] Operational Insights - The decline in revenue was primarily due to a significant drop in the infrared optoelectronic business and underperformance in high-end medical equipment deliveries[5] - The company aims to enhance profitability and operational control by focusing on aerospace defense and deep military-civilian integration industries[5] - The company signed more contracts in the military electronic power business compared to the previous year, indicating growth in this segment[5] - The company will continue to promote cost reduction and efficiency improvement initiatives[5] Research and Development - Research and development expenses for Q1 2025 were CNY 16,345,663.66, up from CNY 15,302,272.41 in Q1 2024, representing an increase of approximately 6.83%[20] - Research and development expenses for Q1 2025 were CNY 3,141,377.34, down from CNY 5,663,258.21 in Q1 2024, indicating a reduction of 44.4%[30] Shareholder Information - The top shareholder, China Aerospace Science and Industry Corporation, holds 30.1% of the shares[10] Government Support - The company received government subsidies amounting to CNY 3,407,911.50, which are closely related to its normal business operations[7] Financial Management - The company will not apply new accounting standards starting from 2025, maintaining current reporting practices[35] - The company's financial management team is led by key personnel including Xiao Haichao, Wang Xuan, and Sun Huajun, ensuring oversight of accounting practices[34]

关于北京航天长峰股份有限公司 2024 年度募集资金存放与实际使用情况 鉴证报告 致同会计师事务所 (特殊普通合伙) n ■ ■ ■ 日 I I I I I ■ I H I I 目 录 关于北京航天长峰股份有限公司 2024年度募集资金 存放与实际使用情况鉴证报告 北京航天长峰股份有限公司 2024年度募集资金 存放与实际使用情况的专项报告 1-4 ■ t Thornton #2 |三| 我们接受委托,对后附的北京航天长峰股份有限公司(以下简称 航天长 峰公司）《2024 年度募集资金存放与实际使用情况的专项报告》（以下简称 "专项报告"）执行了合理保证的鉴证业务。 按照《上市公司监管指引第2号一一上市公司募集资金管理和使用的监管 要求（2022年修订）》和《上海证券交易所上市公司自律监管指引第１号—— 规范运作》的要求编制 2024年度专项报告,保证其内容真实、准确、完整, 不存在虚假记录、误导性陈述或重大遗漏是航天长峰公司董事会的责任,我 们的责任是在实施鉴证工作的基础上对航天长峰公司董事会编制的 2024 年度 专项报告提出鉴证结论。 我们按照《中国注册会计师其他鉴证业务准则第 3101 号一历史财务信 ...

关于北京航天长峰股份有限公司 涉及财务公司关联交易的存款、贷款 等金融业务的专项说明 致同会计师事务所（特殊普通合伙） I n I 日 | I ロ ■ 日 n I F ■ 日 日 ■ F ■ n 录 关于北京航天长峰股份有限公司涉及财务公司 关联交易的存款、贷款等金融业务的专项说明 北京航天长峰股份有限公司 2024年度通过航天科工财务公司 存款、贷款等金融业务汇总表 n n l ■ n n n 1 ■ n 按照《上海证券交易所上市公司自律监管指引第5号——交易与关联交易》 的要求,航天长峰公司编制了本专项说明所附的《北京航天长峰股份有限公 司 2024 年度通过航天科工财务公司存款、贷款等金融业务汇总表》（以下简 称"汇总表")。 编制和对外披露汇总表,并确保其真实性、合法性及完整性是航天长峰 公司管理层的责任。我们对汇总表所载资料与我们审计航天长峰公司 2024 年 度财务报表时所复核的会计资料和经审计的财务报表的相关内容进行了核对, 在所有重大方面没有发现不一致。除了对航天长峰公司实施于 2024 年度财务 报表审计中所执行的对关联方和关联交易的相关审计程序外,我们并未对汇 总表所载资料执行额外的审计程 ...